Quantum Biopharma (NASDAQ:QNTM), Inc. (NASDAQ: QNTM) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small‐molecule therapeutics for oncology, immunology and metabolic disorders. Headquartered in Weston, Florida, with research facilities in Massachusetts, the company leverages its proprietary medicinal chemistry platform to identify novel compounds that modulate disease pathways with high specificity and favorable safety profiles.
The company’s pipeline includes several lead programs targeting solid tumors and hematologic malignancies, as well as preclinical candidates aimed at chronic inflammatory and fibrotic conditions. Quantum Biopharma’s flagship oncology asset is currently undergoing Phase 1/2 trials, evaluating its ability to inhibit tumor growth by selectively binding to kinase receptors involved in cell proliferation. In parallel, the immunology portfolio advances small‐molecule inhibitors designed to suppress aberrant immune responses in autoimmune diseases.
Since its founding in 2005, Quantum Biopharma has forged strategic collaborations with academic institutions, contract research organizations and specialty pharmaceutical partners to accelerate development timelines and expand its geographic reach. The company’s programs benefit from a network of research sites across North America and Europe, with plans to extend into the Asia‐Pacific region through licensing agreements. These partnerships aim to streamline clinical trial operations and facilitate eventual regulatory filings in multiple jurisdictions.
Quantum Biopharma is led by President and Chief Executive Officer Steven L. Wyman, a biopharma veteran with over 25 years of experience at leading pharmaceutical companies, and Chief Scientific Officer Dr. Lisa M. Chang, an expert in drug discovery and translational research. Supported by a management team with deep expertise in clinical development, regulatory affairs and commercial strategy, the company remains committed to advancing its pipeline toward regulatory milestones and delivering novel therapeutics to patients in need.
